Other substances

Rutin

A flavonoid-3-O-glycoside.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Rutin is a natural bioactive quercetin O-glucoside with antioxidant properties (ChEBI).

Rutin on DrugBank
Rutin on PubChem
Rutin on Wikipedia

Synonyms

Rutoside; Quercetin-3-O-rutinoside; Sophorin

C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease 3CLpro Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Sep/08/2020
In silico identification of drug candidates against COVID-19 3CLpro RdRpol	in silico	2.11	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Oct/20/2020
Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy 3CLpro Small molecule In silico	in silico	3.59	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Sep/29/2020
Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6 IL-6 Small molecule In silico	in silico	2.94	Predicted to downregulate IL-6.	Nov/04/2020
Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity Assay PapainLpro Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay	3.69	Inhibits (ca. 50% at 100 μM) SARS-CoV-2 Papain-like protease deubiquitinase activity in vitro in a concentration-dependent manner.	Dec/08/2020
Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins 3CLpro PapainLpro RdRpol Small molecule In silico	in silico	3.08	Predicted to inhibit the SARS-CoV-2 3C-like protease, with predicted binding affinities also for the RNA-dependent RNA polymerase and the Papain-like protease.	Jan/22/2021
Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro Small molecule In silico	in silico	8.99	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jan/07/2021
In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19 Spike protein 3CLpro Small molecule In silico	in silico	4.19	Predicted to inhibit SARS-CoV-2 3C-like protease and Spike protein RBD.	Jan/19/2021
Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs 3CLpro Biophysical assay Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay; in vitro biophysical assay	6.08	The compound bound and inhibited SARS-CoV-2 3C-like protease in vitro.	Apr/02/2021

AI-suggested references

Link	Publication date
Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.	Jun/11/2021
Synthesis, structural, spectral, antioxidant, bioactivity and molecular docking investigations of a novel triazole derivative.	Oct/06/2020
Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.	Nov/03/2020
Potential of (Citrus nobilis Lour x Citrus deliciosa Tenora) metabolites on COVID-19 virus main protease supported by in silico analysis.	May/05/2021
Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.	Sep/01/2021
Study on the mechanism of active components of Liupao tea on 3CLpro based on HPLC-DAD fingerprint and molecular docking technique.	Jul/05/2021
Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3beta: A Putative Target to Combat Mortality in Patients with COVID-19.	Aug/03/2022
Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.	Feb/08/2022
Promising therapeutic approach for SARS-CoV-2 infection by using a rutin-based combination therapy.	May/24/2022
Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.	Nov/18/2020
In Silico Studies Reveal Antiviral Effects of Traditional Indian Spices on COVID-19.	Dec/29/2020
Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its MPRO Main Protease.	Jan/29/2021
Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease	May/27/2020
Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms	Oct/28/2021
Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.	May/24/2021
Identification of Berbamine, Oxyacanthine and Rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: An in silico study	Oct/11/2021
An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods.	May/08/2021
Computational screening of natural compounds from Salvia plebeia R. Br. for inhibition of SARS-CoV-2 main protease	Oct/01/2021
SARS-CoV-2 Inhibitors from Nigella Sativa	Feb/01/2022
Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics.	Jul/19/2021
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study	May/13/2020
Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia	Feb/01/2021
A Report on Multi-Target Anti-Inflammatory Properties of Phytoconstituents from Monochoria hastata (Family: Pontederiaceae)	Dec/06/2021
Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study	Mar/10/2021
Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors	Dec/26/2021
Exploring the inhibitory potential of Saussurea costus and Saussurea involucrata phytoconstituents against the Spike glycoprotein receptor binding domain of SARS-CoV-2 Delta (B.1.617.2) variant and the main protease (Mpro) as therapeutic candidates, using	Apr/09/2022
Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019	Dec/29/2020
Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19	Oct/29/2022
Molecular docking analysis of SARS-CoV-2 linked RNA dependent RNA polymerase (RdRp) with compounds from Plectranthus amboinicus	May/30/2022
Rescuing the Host Immune System by Targeting the Immune Evasion Complex ORF8-IRF3 in SARS-CoV-2 Infection with Natural Products Using Molecular Modeling Approaches	Dec/03/2021
l-Arginine Improves Solubility and ANTI SARS-CoV-2 Mpro Activity of Rutin but Not the Antiviral Activity in Cells	Oct/07/2021
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.	Feb/09/2021
Interaction of 8-anilinonaphthalene-1-sulfonate with SARS-CoV-2 main protease and its application as a fluorescent probe for inhibitor identification.	Jun/05/2021
Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)	Sep/30/2020
Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.	Mar/20/2021
Potential role of medicinal plants and their constituents in the mitigation of SARS-CoV-2: identifying related therapeutic targets using network pharmacology and molecular docking analyses	Oct/13/2020
Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking	Apr/08/2021
Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin	Dec/27/2020
Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro.	Dec/23/2020
In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.	Apr/05/2021
Wild Sambucus nigra L. from north-east edge of the species range: A valuable germplasm with inhibitory capacity against SARS-CoV2 S-protein RBD and hACE2 binding in vitro.	Mar/18/2021
In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2.	Sep/21/2021
Inhibition of SARS-CoV-2 main protease by phenolic compounds from Manilkara hexandra (Roxb.) Dubard assisted by metabolite profiling and in silico virtual screening	Apr/17/2022
In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (Mpro) from flavonoid based phytochemical constituents of Calendula officinalis	Apr/05/2022
Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19)	Jan/04/2021
Semi-Synthesis of N-Aryl Amide Analogs of Piperine from Piper nigrum and Evaluation of Their Antitrypanosomal, Antimalarial, and Anti-SARS-CoV-2 Main Protease Activities	Apr/29/2022
Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies	Feb/25/2022
Pimenta dioica (L.) Merr. Bioactive Constituents Exert Anti-SARS-CoV-2 and Anti-Inflammatory Activities: Molecular Docking and Dynamics, In Vitro, and In Vivo Studies	Apr/07/2022
Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines	Sep/18/2021
Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach	Jun/01/2020
Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies	Oct/15/2020
Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease.	May/24/2021
Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: In silico and in vitro studies	Sep/15/2021
Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology	May/25/2021
Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity	Nov/12/2020
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2	Mar/29/2020
Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.	Apr/12/2022
Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)	Nov/10/2020
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches	Jul/05/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04382586	Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants	Completed	Phase 2	Jul/06/2020	Feb/01/2021
Alternative id - BGB-3111-219 Interventions - Drug: Zanubrutinib\|Drug: Supportive Care\|Drug: Placebo Study type - Interventional Study results - Has Results Locations - Honor Health, Scottsdale, Arizona, United States\|St. Jude Medical Center, Fullerton, California, United States\|Olive View - UCLA Medical Center, Sylmar, California, United States\|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States\|Augusta University, Augusta, Georgia, United States\|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States\|Loyola University Medical Center, Maywood, Illinois, United States\|SIU School of Medicine, Springfield, Illinois, United States\|University of Iowa, Iowa City, Iowa, United States\|Massachusetts General Hospital, Boston, Massachusetts, United States\|Brigham And Women's Hospital, Boston, Massachusetts, United States\|Morristown Medical Center, Morristown, New Jersey, United States\|Rutgers University Hospital, Newark, New Jersey, United States\|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States\|Overlook Medical Center, Summit, New Jersey, United States\|Therapeutic Concepts, Houston, Texas, United States\|Covenant Health System, Lubbock, Texas, United States\|Medical College of Wisconsin, Milwaukee, Wisconsin, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 63 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of Participants With Respiratory Failure-free Survival\|Time to Breathing Room Air\|Number of Participants Experiencing Respiratory Failure or Death\|Number of Participants With All-cause Mortality\|Number of Participants Discharged Alive\|Number of Participants Discharged Alive From the ICU\|Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale\|Duration of Mechanical Ventilation\|Duration of Hospitalization\|PaO2:FiO2 Ratio\|Number of Participants With Adverse Events
NCT04346199	Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.	Completed	Phase 2	Jun/12/2020	Nov/17/2020
Alternative id - D822FC00001 Interventions - Drug: Acalabrutinib Study type - Interventional Study results - Has Results Locations - Research Site, Ciudad de Buenos Aires, Argentina\|Research Site, Ciudad de Buenos Aires, Argentina\|Research Site, Monte Grande, Argentina\|Research Site, Ramos Mejía, Argentina\|Research Site, Botucatu, Brazil\|Research Site, Brasillia, Brazil\|Research Site, Florianópolis, Brazil\|Research Site, Porto Alegre, Brazil\|Research Site, Porto Alegre, Brazil\|Research Site, Ribeirão Preto, Brazil\|Research Site, Salvador, Brazil\|Research Site, Sao Bernardo do Campo, Brazil\|Research Site, Sao Paulo, Brazil\|Research Site, Sao Paulo, Brazil\|Research Site, São Paulo, Brazil\|Research Site, Curico, Chile\|Research Site, Santiago, Chile\|Research Site, Talca, Chile\|Research Site, Villejuif Cedex, France\|Research Site, Frankfurt, Germany\|Research Site, Gauting, Germany\|Research Site, Köln, Germany\|Research Site, Bangalore, India\|Research Site, New Delhi, India\|Research Site, Milano, Italy\|Research Site, Roma, Italy\|Research Site, Shinjuku-ku, Japan\|Research Site, D.F, Mexico\|Research Site, Monterrey, Mexico\|Research Site, México, Mexico\|Research Site, Lima, Peru\|Research Site, Lima, Peru\|Research Site, Lima, Peru\|Research Site, Warszawa, Poland\|Research Site, Warszawa, Poland\|Research Site, Moscow, Russian Federation\|Research Site, Moscow, Russian Federation\|Research Site, Moscow, Russian Federation\|Research Site, Moscow, Russian Federation\|Research Site, Murmansk, Russian Federation\|Research Site, Cape Town, South Africa\|Research Site, George, South Africa\|Research Site, Johannesburg, South Africa\|Research Site, Johannesburg, South Africa\|Research Site, Pretoria, South Africa\|Research Site, Ankara, Turkey\|Research Site, Bakirkoy, Turkey\|Research Site, Istanbul, Turkey\|Research Site, Istanbul, Turkey\|Research Site, Umraniye, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 177 Age - 18 Years to 130 Years (Adult, Older Adult) Outcome measures - Percentage of Participants Alive and Free of Respiratory Failure at Day 14\|Number of Participants With Adverse Events and Serious Adverse Events\|Percentage of Participants Alive and Free of Respiratory Failure at Day 28\|Percent Change From Baseline in C-reactive Protein.\|Percent Change From Baseline in Ferritin\|Percent Change From Baseline in Absolute Lymphocyte Count\|Overall Survival\|Percentage of Participants Alive and Discharged From ICU\|Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause\|Number of Days Alive and Free of Respiratory Failure\|Number of Days With Respiratory Failure\|Number of Days Hospitalized\|Number of Days in ICU\|Number of Days Alive Outside of Hospital\|Percent Change From Baseline in Oxygenation Index\|Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale\|Pharmacokinetics of Acalabrutinib\|Pharmacokinetics of ACP-5862
NCT04497948	Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19	Terminated	Phase 1	Sep/21/2020	Nov/18/2020
Alternative id - D822FC00005 Interventions - Drug: Acalabrutinib Study type - Interventional Study results - Has Results Locations - Research Site, Porto Alegre, Brazil\|Research Site, Ribeirão Preto, Brazil\|Research Site, Sao Paulo, Brazil\|Research Site, Sao Paulo, Brazil Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 9 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Area Under the Concentration-time Curve From 0 to 12 Hours (AUC12h) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)\|Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)\|Maximum Observed Plasma Concentration (Cmax) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2(Day2) and Visit 3 (Day 5)
NCT04647669	World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments	Not yet recruiting	Phase 3	Jun/01/2021	Dec/31/2021
Alternative id - SRD/ETH/20 Interventions - Drug: Remdesivir\|Drug: Acalabrutinib\|Drug: Interferon beta-1a\|Other: Standard of Care Study type - Interventional Study results - No Results Available Locations - Univeristy of the West Indies, Kingston, Jamaica Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - All cause Mortality\|Duration of hospital stay\|Time to first receiving ventilation\|Time to admission to the intensive care unit
NCT04564040	A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole	Completed	Phase 1	Oct/12/2020	Dec/11/2020
Alternative id - D8223C00005 Interventions - Drug: Acalabrutinib Treatment A\|Drug: Acalabrutinib Treatment B\|Drug: Acalabrutinib Treatment C\|Drug: Acalabrutinib Treatment D Study type - Interventional Study results - No Results Available Locations - Research Site, Berlin, Germany Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 20 Age - 18 Years to 55 Years (Adult) Outcome measures - Part 1 and 2: Area under plasma concentration-time curve from time zero to infinity (AUCinf)\|Part 1 and 2: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)\|Part 1 and Part 2: Maximum observed plasma concentration (Cmax)\|Part 1 and Part 2: Area under the plasma concentration-time curve from time zero to 24 hours post dose (AUC0-24)\|Part 1 and 2: Time to reach maximum observed plasma concentration (tmax)\|Part 1 and 2: Half-life associated with terminal slope (λz) of a semi-logarithmic concentrationtime curve (t1/2)\|Part 1 and 2: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)\|Part 1 and 2: Terminal elimination rate constant (λz)\|Part 1 and 2: Apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (CL/F)\|Part 1 and 2: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)\|Part 1 and 2: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])\|Part 1 and 2: Metabolite to parent ratio based on Cmax (M:P[Cmax])\|Number of subjects with serious and non-serious adverse events
NCT04380688	Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.	Completed	Phase 2	Jun/13/2020	Nov/16/2020
Alternative id - D822FC00003 Interventions - Drug: Acalabrutinib Study type - Interventional Study results - Has Results Locations - Research Site, Anniston, Alabama, United States\|Research Site, Mobile, Alabama, United States\|Research Site, Escondido, California, United States\|Research Site, Fullerton, California, United States\|Research Site, Glendale, California, United States\|Research Site, Newport Beach, California, United States\|Research Site, New Haven, Connecticut, United States\|Research Site, Washington, District of Columbia, United States\|Research Site, Fort Lauderdale, Florida, United States\|Research Site, Jacksonville, Florida, United States\|Research Site, Jacksonville, Florida, United States\|Research Site, Loxahatchee Groves, Florida, United States\|Research Site, Fort Wayne, Indiana, United States\|Research Site, Louisville, Kentucky, United States\|Research Site, Annapolis, Maryland, United States\|Research Site, Baltimore, Maryland, United States\|Research Site, Bethesda, Maryland, United States\|Research Site, Bethesda, Maryland, United States\|Research Site, Silver Spring, Maryland, United States\|Research Site, Hackensack, New Jersey, United States\|Research Site, Albany, New York, United States\|Research Site, Bronx, New York, United States\|Research Site, Buffalo, New York, United States\|Research Site, New York, New York, United States\|Research Site, Philadelphia, Pennsylvania, United States\|Research Site, Nashville, Tennessee, United States\|Research Site, Houston, Texas, United States\|Research Site, Houston, Texas, United States\|Research Site, Tyler, Texas, United States\|Research Site, Richmond, Virginia, United States\|Research Site, Renton, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 62 Age - 18 Years to 130 Years (Adult, Older Adult) Outcome measures - Number of Participants With Adverse Events and Serious Adverse Events\|Percentage of Participants Alive and Free of Respiratory Failure at Day 28\|Percentage of Participants Alive and Free of Respiratory Failure at Day 14\|Percent Change From Baseline in C-reactive Protein.\|Percent Change From Baseline in Ferritin\|Percent Change From Baseline in Absolute Lymphocyte Count\|Overall Survival\|Percentage of Participants Alive and Discharged From ICU\|Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause\|Number of Days Alive and Free of Respiratory Failure\|Number of Days With Respiratory Failure\|Number of Days Hospitalized\|Number of Days in ICU\|Number of Days Alive Outside of Hospital\|Percent Change From Baseline in Oxygenation Index\|Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale\|Pharmacokinetics of Acalabrutinib\|Pharmacokinetics of ACP-5862
NCT04665115	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	Withdrawn	Phase 2	Dec/01/2021	May/01/2025
Alternative id - ACCRU-LY-2001\|NCI-2020-11785\|P30CA015083 Interventions - Drug: Ibrutinib\|Other: Quality-of-Life Assessment Study type - Interventional Study results - No Results Available Locations - Mayo Clinic in Rochester, Rochester, Minnesota, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients who require hospitalization for their COVID-19 disease or die (Cohort 1)\|Proportion of patients who require mechanical ventilation and/or die (Cohort 2)\|Rate of "flare phenomena" (Cohort I)\|Patient-reported health and symptom status (Cohort I)\|Patterns on ibrutinib therapy during COVID-19 infection (Cohort I)\|Reasons for hospitalization (Cohort I)\|Mortality (Cohort II)\|Time to hospital discharge (Cohort II)\|Intubation and oxygen supplementation (Cohort II)\|Incidence of "flare phenomena" (Cohort II)\|Viral clearance\|Development of COVID-19 antibodies\|Coagulopathy and thrombosis measures\|Cytokine measures\|Immune subset measures
NCT04375397	Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury	Completed	Phase 2	Jun/06/2020	Jun/08/2021
Alternative id - M20-310 Interventions - Drug: Ibrutinib\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Stanford Univ School Medicine /ID# 221954, Stanford, California, United States\|Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States\|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States\|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States\|University of Miami /ID# 223227, Miami, Florida, United States\|Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States\|Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States\|Beth Israel Deaconess Medical Center /ID# 222994, Boston, Massachusetts, United States\|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 46 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Percentage of Participants Alive and Without Respiratory Failure\|Change in the World Health Organization (WHO)-8 Point Ordinal Scale From Baseline\|Median Reduction in Days Spent on Supplemental Oxygen\|All-Cause Mortality\|Percentage of Participants Experiencing Respiratory Failure or Death\|Mechanical Ventilation-Free Survival\|Days on Mechanical Ventilation\|Duration of hospitalization\|Time to Discharge\|Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio\|Oxygenation Index\|Number of Participants With Adverse Events\|Number of Participants With Abnormal Laboratory Findings
NCT05024006	Public Health Emergency: SOLIDARITY TRIAL Philippines	Completed	Not Applicable	Apr/23/2020	Apr/17/2021
Alternative id - SJREB-2020-20 Interventions - Drug: Remdesivir\|Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir\|Drug: Interferon beta-1a\|Drug: Acalabrutinib Study type - Interventional Study results - No Results Available Locations - Baguio General Hospital, Baguio City, Benguet, Philippines\|Cebu Doctor's University Hospital, Cebu City, Cebu, Philippines\|Perpetual Succor Hospital Cebu, Cebu City, Cebu, Philippines\|Vicente Sotto Memorial Medical Center, Cebu City, Cebu, Philippines\|Southern Philippines Medical Center, Davao City, Davao, Philippines\|West Visayas University Medical Center, Iloilo City, Iloilo, Philippines\|Makati Medical Center, Makati City, Metro Manila, Philippines\|Chinese General Hospital, Manila, Metro Manila, Philippines\|Manila Doctors Hospital, Manila, Metro Manila, Philippines\|ManilaMed - Medical Center Philippines, Manila, Metro Manila, Philippines\|San Lazaro Hospital, Manila, Metro Manila, Philippines\|UP - Philippine General Hospital, Manila, Metro Manila, Philippines\|Asian Hospital and Medical Center, Muntinlupa, Metro Manila, Philippines\|Research Institute for Tropical Medicine, Muntinlupa, Metro Manila, Philippines\|San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines\|The Medical City, Pasig City, Metro Manila, Philippines\|Diliman Doctors Hospital, Quezon City, Metro Manila, Philippines\|Fe Del Mundo Medical Center, Quezon City, Metro Manila, Philippines\|Lung Center of the Philippines, Quezon City, Metro Manila, Philippines\|St Luke's Medical Center Quezon City, Quezon City, Metro Manila, Philippines\|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines\|World Citi Medical Center, Quezon City, Metro Manila, Philippines\|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines\|St Luke's Medical Center Global, Taguig, Metro Manila, Philippines\|Batangas Medical Center, Batangas, Philippines Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1314 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Duration of hospital stay\|Time to first receiving ventilation
NCT04439006	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	Active, not recruiting	Phase 2	Oct/23/2020	Dec/31/2023
Alternative id - OSU-20135\|NCI-2020-03341 Interventions - Other: Best Practice\|Drug: Ibrutinib Study type - Interventional Study results - No Results Available Locations - Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients with diminished respiratory failure and death\|Death\|Time from study initiation to 48 hours fever-free\|Duration of hospitalization\|Time in intensive care unit (ICU)\|Time to ICU admission\|Number of days requiring supplemental oxygen\|Total days of mechanical ventilation\|Time to mechanical ventilation\|Shock and need for pressure support\|Incidence of any infection (viral, fungal, bacterial)\|Time to clinical resolution\|Incidence of grade 3 or higher adverse events\|At the end of therapy (day 14)\|Time to viral clearance\|Survival

Export (.csv)